BioCentury
ARTICLE | Finance

Weighing exchanges

How diabetes play Hua is choosing between Hong Kong and the U.S. for its IPO

January 26, 2018 12:16 AM UTC

Hua Medicine Ltd. is weighing the merits of pursuing an IPO in Hong Kong versus the U.S. ahead of the expected launch of lead candidate dorzagliatin in China.

The Shanghai company’s financing strategy will be led by EVP and CFO George Lin, who joined Hua in December. He was previously head of consumer, retail and healthcare investment banking for Asia Pacific and head of investment banking coverage for Hong Kong and Taiwan at Bank of America Corp. (NYSE:BAC). ...